Literature DB >> 35880813

Management of opioid use disorder and associated conditions among hospitalized adults: A Consensus Statement from the Society of Hospital Medicine.

Susan L Calcaterra1, Marlene Martin2, Richard Bottner3, Honora Englander4, Zoe Weinstein5, Melissa B Weimer6, Eugene Lambert7, Shoshana J Herzig7,8.   

Abstract

Hospital-based clinicians frequently care for patients with opioid withdrawal or opioid use disorder (OUD) and are well-positioned to identify and initiate treatment for these patients. With rising numbers of hospitalizations related to opioid use and opioid-related overdose, the Society of Hospital Medicine convened a working group to develop a Consensus Statement on the management of OUD and associated conditions among hospitalized adults. The guidance statement is intended for clinicians practicing medicine in the inpatient setting (e.g., hospitalists, primary care physicians, family physicians, advanced practice nurses, and physician assistants) and is intended to apply to hospitalized adults at risk for, or diagnosed with, OUD. To develop the Consensus Statement, the working group conducted a systematic review of relevant guidelines and composed a draft statement based on extracted recommendations. Next, the working group obtained feedback on the draft statement from external experts in addiction medicine, SHM members, professional societies, harm reduction organizations and advocacy groups, and peer reviewers. The iterative development process resulted in a final Consensus Statement consisting of 18 recommendations covering the following topics: (1) identification and treatment of OUD and opioid withdrawal, (2) perioperative and acute pain management in patients with OUD, and (3) methods to optimize care transitions at hospital discharge for patients with OUD. Most recommendations in the Consensus Statement were derived from guidelines based on observational studies and expert consensus. Due to the lack of rigorous evidence supporting key aspects of OUD-related care, the working group identified important issues necessitating future research and exploration.
© 2022 Society of Hospital Medicine.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35880813      PMCID: PMC9474708          DOI: 10.1002/jhm.12893

Source DB:  PubMed          Journal:  J Hosp Med        ISSN: 1553-5592            Impact factor:   2.899


  117 in total

Review 1.  Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice.

Authors:  Stacey C Sigmon; Adam Bisaga; Edward V Nunes; Patrick G O'Connor; Thomas Kosten; George Woody
Journal:  Am J Drug Alcohol Abuse       Date:  2012-03-12       Impact factor: 3.829

Review 2.  Perioperative Management of Buprenorphine: Solving the Conundrum.

Authors:  Aurora Naa-Afoley Quaye; Yi Zhang
Journal:  Pain Med       Date:  2019-07-01       Impact factor: 3.750

Review 3.  Acute pain management for patients receiving maintenance methadone or buprenorphine therapy.

Authors:  Daniel P Alford; Peggy Compton; Jeffrey H Samet
Journal:  Ann Intern Med       Date:  2006-01-17       Impact factor: 25.391

4.  Confronting the stigma of opioid use disorder--and its treatment.

Authors:  Yngvild Olsen; Joshua M Sharfstein
Journal:  JAMA       Date:  2014-04-09       Impact factor: 56.272

5.  Confronting inadvertent stigma and pejorative language in addiction scholarship: a recognition and response.

Authors:  Lauren M Broyles; Ingrid A Binswanger; Jennifer A Jenkins; Deborah S Finnell; Babalola Faseru; Alan Cavaiola; Marianne Pugatch; Adam J Gordon
Journal:  Subst Abus       Date:  2014       Impact factor: 3.716

6.  Methadone analgesia in cancer pain patients on chronic methadone maintenance therapy.

Authors:  P L Manfredi; G R Gonzales; A L Cheville; C Kornick; R Payne
Journal:  J Pain Symptom Manage       Date:  2001-02       Impact factor: 3.612

Review 7.  Hydroxyzine for generalised anxiety disorder.

Authors:  Giuseppe Guaiana; Corrado Barbui; Andrea Cipriani
Journal:  Cochrane Database Syst Rev       Date:  2010-12-08

Review 8.  QTc interval screening for cardiac risk in methadone treatment of opioid dependence.

Authors:  Pier Paolo Pani; Emanuela Trogu; Icro Maremmani; Matteo Pacini
Journal:  Cochrane Database Syst Rev       Date:  2013-06-20

9.  Prevention of Hepatitis A Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020.

Authors:  Noele P Nelson; Mark K Weng; Megan G Hofmeister; Kelly L Moore; Mona Doshani; Saleem Kamili; Alaya Koneru; Penina Haber; Liesl Hagan; José R Romero; Sarah Schillie; Aaron M Harris
Journal:  MMWR Recomm Rep       Date:  2020-07-03

10.  Cost-effectiveness of integrating buprenorphine-naloxone treatment for opioid use disorder into clinical care for persons with HIV/hepatitis C co-infection who inject opioids.

Authors:  Joshua A Barocas; Jake R Morgan; David A Fiellin; Bruce R Schackman; Golnaz Eftekhari Yazdi; Michael D Stein; Kenneth A Freedberg; Benjamin P Linas
Journal:  Int J Drug Policy       Date:  2019-05-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.